Literature DB >> 27824842

CAR-T cells forge ahead, Novartis reorganizes.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27824842     DOI： 10.1038/nbt1116-1079

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  9 in total

1.  Regulation of cutaneous malignancy by gammadelta T cells.

Authors:  M Girardi; D E Oppenheim; C R Steele; J M Lewis; E Glusac; R Filler; P Hobby; B Sutton; R E Tigelaar; A C Hayday
Journal:  Science       Date:  2001-09-20       Impact factor: 47.728

2.  Off-the-shelf CAR-T therapy induces remission in child with ALL.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

3.  CAR-T cell therapy seeks strategies to harness cytokine storm.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2014-07       Impact factor: 54.908

4.  T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Authors:  Syed Abbas Ali; Victoria Shi; Irina Maric; Michael Wang; David F Stroncek; Jeremy J Rose; Jennifer N Brudno; Maryalice Stetler-Stevenson; Steven A Feldman; Brenna G Hansen; Vicki S Fellowes; Frances T Hakim; Ronald E Gress; James N Kochenderfer
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

5.  Juno's wild ride.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2016-08-09       Impact factor: 54.908

6.  RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2016-02-24       Impact factor: 13.506

7.  CAR-T field booms as next-generation platforms attract big players.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2015-06       Impact factor: 54.908

8.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

9.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113
  9 in total
  3 in total

1.  First approval in sight for Novartis' CAR-T therapy after panel vote.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2017-08-08       Impact factor: 54.908

2.  Reference Standards for Gene and Cell Therapy Products.

Authors:  Boro Dropulić
Journal:  Mol Ther       Date:  2017-05-11       Impact factor: 11.454

3.  Epic $12 billion deal and FDA's approval raise CAR-T to new heights.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-10-11       Impact factor: 54.908
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.